Albert Kandra
Overview
Explore the profile of Albert Kandra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gadelha M, Gu F, Bronstein M, Brue T, Fleseriu M, Shimon I, et al.
Endocr Connect
. 2021 Jan;
9(12):1178-1190.
PMID: 33434154
Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for somatostatin receptor subtype (SST) 5, has demonstrated superior efficacy over the SST2-preferential somatostatin analogs octreotide and lanreotide. The safety profile is...
2.
Lacroix A, Gu F, Schopohl J, Kandra A, Pedroncelli A, Jin L, et al.
Pituitary
. 2019 Dec;
23(3):203-211.
PMID: 31875276
Purpose: In the multinational, randomized, double-blind, Phase 3 B2305 study of patients with Cushing's disease (CD; ClinicalTrials.gov identifier NCT00434148), pasireotide substantially decreased urinary-free cortisol (UFC) levels, decreased mean corticotroph tumor...
3.
Foltz L, Pica G, Zerazhi H, van Droogenbroeck J, Visanica S, Baez de la Fuente E, et al.
Leuk Lymphoma
. 2019 Jul;
60(14):3493-3502.
PMID: 31359808
Ruxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Expanded Treatment Protocol...
4.
Findling J, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, et al.
Endocrine
. 2016 May;
54(2):516-523.
PMID: 27209465
Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism. This analysis reports changes in late-night salivary cortisol (LNSC) during a 12-month,...
5.
Greene S, Maggioni A, Fonarow G, Solomon S, Bohm M, Kandra A, et al.
Eur J Heart Fail
. 2015 Jan;
17(1):98-108.
PMID: 25597870
Aims: The purpose of this study was to determine the prognostic significance and associated clinical profile of early post-discharge N-terminal pro-B-type natriuretic peptide (NT-proBNP) trajectory among patients hospitalized for worsening...
6.
Zappe D, Crikelair N, Kandra A, Palatini P
J Hypertens
. 2014 Sep;
33(2):385-92.
PMID: 25259546
Objective: Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP)...
7.
Lesogor A, Cohn J, Latini R, Tognoni G, Krum H, Massie B, et al.
Eur J Heart Fail
. 2013 Jun;
15(11):1236-44.
PMID: 23787721
Aims: We evaluated the effect of (dual) renin-angiotensin-aldosterone system (RAAS) blockade with valsartan and an ACE inhibitor [92.7% of patients were treated with an ACE inhibitor in the Valsartan in...
8.
Hayoz D, Zappe D, Meyer M, Baek I, Kandra A, Joly M, et al.
J Clin Hypertens (Greenwich)
. 2012 Nov;
14(11):773-8.
PMID: 23126349
Postmenopausal women are at greater risk for hypertension-related cardiovascular disease. Antihypertensive therapy may help alleviate arterial stiffness that represents a potential modifiable risk factor of hypertension. This randomized controlled study...
9.
Krum H, Massie B, Abraham W, Dickstein K, Kober L, McMurray J, et al.
Eur J Heart Fail
. 2010 Dec;
13(1):107-14.
PMID: 21169387
The renin-angiotensin-aldosterone system (RAAS) represents a key therapeutic target in heart failure (HF) management. However, conventional agents that block this system induce a reflex increase in plasma renin activity (PRA),...
10.
Parati G, Asmar R, Bilo G, Kandra A, Di Giovanni R, Mengden T
Hypertens Res
. 2010 Aug;
33(10):986-94.
PMID: 20686486
Early combination therapy is increasingly recommended in hypertension management because of increased risk of adverse effects with high-dose monotherapy. However, this risk is not necessarily increased for high doses of...